|Last Price$32.87||Day Change (%)2.82%|
|Open Price$32.36||Day Change ($)0.90|
|Day Range32.20–33.24||52-Week Range28.47–36.46|
As of Thu 11/25/2015 7:53:00 PM | USD
Fitch Places Pfizer's L-T Ratings on Negative Watch Following Allergan Merger Announcement
Progenics Pharmaceuticals PGNX and partner Wyeth WYE announced Thursday that both the Food and Drug Administration and the European Medicines Agency have accepted new drug applications for subcutaneous MNTX, which aims to treat postoperative ileus and opioid bowel dysfunction. We are leaving our ...
Pfizer Piles Profits Abroad
Pfizer's Accounting Method Leads to Higher Effective Tax Rate in U.S.
Touchpoint Dashboard Completely Transforms Customer Journey Mapping to Journey Management Through Addition of Action Planning
Inside Clipper Fund's makeover.
Recent deals have been driven more by tax strategies than therapeutic synergies.
Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.
Things look grim, but investors who can bear it could benefit.